Differences in response to antiretroviral therapy in HIV-positive patients being treated for tuberculosis in Eastern Europe, Western Europe and Latin America

Table 5 Risk factors for loss to follow-up

	Univariate model		Multivariate model
	Hazard Ratio (95% confidence interval)	p-value	Hazard Ratio (95% confidence interval)	p-value
Region		< 0.01		< 0.01
Eastern Europe	1		1
Western/Southern Europe	0.59(0.41–0.84)		0.77(0.50–1.16)
Latin America	0.58(0.39–0.87)		0.64(0.41–1.00)
Age, years		0.59	a
30 vs 20	1.20(0.79–1.83)
40 vs 20	1.20(0.63–2.29)
50 vs 20	0.82(0.85–1.50)
Male	1.00(0.73–1.40)	0.96	0.90(0.64–1.28)	0.56
Disseminated TB	0.89(0.66–1.19)	0.44	0.93(0.68–1.26)	0.62
IDU	1.25(0.93–1.69)	0.13	0.97(0.68–1.37)	0.85
TB susceptibility		0.52		0.84
No MDR vs MDR	0.72(0.41–1.26)		0.92(0.51–1.65)
No Resistance test vs MDR	1.19(0.69–2.05)		1.45(0.83–2.52)
Rifamicin	0.84(0.50–1.41)	0.51	a
Efavirenz	1.38(0.99–1.91)	0.06	1.17(0.81–1.67)	0.40
ART naïve	1.94(1.42–2.65)	< 0.01	a
CD4⁺ at TB diagnosis (cells/mm³)		0.48		0.41
100 vs 50	0.97(0.86–1.10)		0.99(0.90–1.10)
200 vs 50	0.95(0.73–1.25)		0.98(0.79–1.20)
350 vs 50	0.98(0.72–1.34)		0.92(0.73–1.17)

Note: Multivariate Cox model regression stratified by ryfamicin use, naïve condition and age. ^aFor these variables the model was stratified so we do not have specific hazard ratios. Eight hundred fifty-two patients included, only people who died at 12 months were excluded in this model

ISSN: 1471-2334